Rosenberg, G. (2007). “The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?”. Cellular and Molecular Life Sciences64 (16): 2090-2103. doi:10.1007/s00018-007-7079-x. PMID17514356.
Jacobson PL, Messenheimer JA, Farmer TW (1981). “Treatment of intractable hiccups with valproic acid”. Neurology31 (11): 1458. doi:10.1212/WNL.31.11.1458. PMID6796902.
Frazee LA.; Foraker KC. (2008). “Use of intravenous valproic acid for acute migraine”. Ann Pharmacother42 (3): 403-407. doi:10.1345/aph.1K531. PMID18303140.
Glauser, Tracy A.; Cnaan, Avital; Shinnar, Shlomo; Hirtz, Deborah G.; Dlugos, Dennis; Masur, David; Clark, Peggy O.; Capparelli, Edmund V. et al. (2010). “Ethosuximide, Valproic Acid, and Lamotrigine in Childhood Absence Epilepsy”. New England Journal of Medicine362 (9): 790-799. doi:10.1056/NEJMoa0902014. ISSN0028-4793.
Berendsen, S.; Kroonen, J.; Seute, T.; Snijders, T.; Broekman, M. L. D.; Spliet, W. G. M.; Willems, M.; Artesi, M. et al. (2014). “O9.06 * PROGNOSTIC RELEVANCE AND ONCOGENIC CORRELATES OF EPILEPSY IN GLIOBLASTOMA PATIENTS”. Neuro-Oncology16 (suppl 2): ii21. doi:10.1093/neuonc/nou174.77. ISSN1522-8517.
Vasudev K, Mead A, Macritchie K, Young AH (2012). “Valproate in acute mania: is our practice evidence based?”. Int J Health Care Qual Assur25 (1): 41-52. doi:10.1108/09526861211192395. PMID22455007.
Bond DJ, Lam RW, Yatham LN (2010). “Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis.”. J Affect Disord124 (3): 228-334. doi:10.1016/j.jad.2009.11.008. PMID20044142.
Haddad PM, Das A, Ashfaq M, Wieck A (2009). “A review of valproate in psychiatric practice”. Expert Opin Drug Metab Toxicol5 (5): 539-551. doi:10.1517/17425250902911455. PMID19409030.
Siemes H, Spohr HL, Michael T, Nau H (1988). “Therapy of infantile spasms with valproate: results of a prospective study”. Epilepsia29 (5): 553-560. doi:10.1111/j.1528-1157.1988.tb03760.x. PMID2842127.
Candelaria M, Herrera A, Labardini J, Gonzalez-Fierro A, Trejo-Becerril C, Taja-Chayeb L, Perez-Cardenas E, de la Cruz-Hernandez E, Arias-Bofill D, Vidal S, Cervera E, Duenas-Gonzalez A (2011). “Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.”. Ann. Hematol.90 (4): 379-387. doi:10.1007/s00277-010-1090-2. PMID20922525.
Coronel J, Cetina L, Pacheco I, Trejo-Becerril C, Gonzalez-Fierro A, de la Cruz-Hernandez E, Perez-Cardenas E, Taja-Chayeb L, Arias-Bofill D, Candelaria M, Vidal S, Duenas-Gonzalez A (2011). “A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.”. Med. Oncol.28 Suppl 1: S540-S546. doi:10.1007/s12032-010-9700-3. PMID20931299.
Rosenberg, G. (2007). “The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?”. Cellular and Molecular Life Sciences64 (16): 2090-2103. doi:10.1007/s00018-007-7079-x. PMID17514356.
Jacobson PL, Messenheimer JA, Farmer TW (1981). “Treatment of intractable hiccups with valproic acid”. Neurology31 (11): 1458. doi:10.1212/WNL.31.11.1458. PMID6796902.
Vasudev K, Mead A, Macritchie K, Young AH (2012). “Valproate in acute mania: is our practice evidence based?”. Int J Health Care Qual Assur25 (1): 41-52. doi:10.1108/09526861211192395. PMID22455007.
Bond DJ, Lam RW, Yatham LN (2010). “Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis.”. J Affect Disord124 (3): 228-334. doi:10.1016/j.jad.2009.11.008. PMID20044142.
Haddad PM, Das A, Ashfaq M, Wieck A (2009). “A review of valproate in psychiatric practice”. Expert Opin Drug Metab Toxicol5 (5): 539-551. doi:10.1517/17425250902911455. PMID19409030.
Siemes H, Spohr HL, Michael T, Nau H (1988). “Therapy of infantile spasms with valproate: results of a prospective study”. Epilepsia29 (5): 553-560. doi:10.1111/j.1528-1157.1988.tb03760.x. PMID2842127.
Candelaria M, Herrera A, Labardini J, Gonzalez-Fierro A, Trejo-Becerril C, Taja-Chayeb L, Perez-Cardenas E, de la Cruz-Hernandez E, Arias-Bofill D, Vidal S, Cervera E, Duenas-Gonzalez A (2011). “Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.”. Ann. Hematol.90 (4): 379-387. doi:10.1007/s00277-010-1090-2. PMID20922525.
Coronel J, Cetina L, Pacheco I, Trejo-Becerril C, Gonzalez-Fierro A, de la Cruz-Hernandez E, Perez-Cardenas E, Taja-Chayeb L, Arias-Bofill D, Candelaria M, Vidal S, Duenas-Gonzalez A (2011). “A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.”. Med. Oncol.28 Suppl 1: S540-S546. doi:10.1007/s12032-010-9700-3. PMID20931299.
Glauser, Tracy A.; Cnaan, Avital; Shinnar, Shlomo; Hirtz, Deborah G.; Dlugos, Dennis; Masur, David; Clark, Peggy O.; Capparelli, Edmund V. et al. (2010). “Ethosuximide, Valproic Acid, and Lamotrigine in Childhood Absence Epilepsy”. New England Journal of Medicine362 (9): 790-799. doi:10.1056/NEJMoa0902014. ISSN0028-4793.
Berendsen, S.; Kroonen, J.; Seute, T.; Snijders, T.; Broekman, M. L. D.; Spliet, W. G. M.; Willems, M.; Artesi, M. et al. (2014). “O9.06 * PROGNOSTIC RELEVANCE AND ONCOGENIC CORRELATES OF EPILEPSY IN GLIOBLASTOMA PATIENTS”. Neuro-Oncology16 (suppl 2): ii21. doi:10.1093/neuonc/nou174.77. ISSN1522-8517.
